vs
Side-by-side financial comparison of Cellectis S.A. (CLLS) and EXELIXIS, INC. (EXEL). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $9.5M, roughly 63.0× Cellectis S.A.). EXELIXIS, INC. runs the higher net margin — 40.8% vs -265.9%, a 306.7% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $27.6M).
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
CLLS vs EXEL — Head-to-Head
Income Statement — Q2 2024 vs Q4 2026
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $598.7M |
| Net Profit | $-25.3M | $244.5M |
| Gross Margin | — | 95.6% |
| Operating Margin | -181.1% | 39.3% |
| Net Margin | -265.9% | 40.8% |
| Revenue YoY | 375.0% | 5.6% |
| Net Profit YoY | -51.9% | 74.8% |
| EPS (diluted) | $-0.28 | $0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $598.7M | ||
| Q4 25 | — | $597.8M | ||
| Q3 25 | — | $568.3M | ||
| Q2 25 | — | $555.4M | ||
| Q1 25 | — | $566.8M | ||
| Q3 24 | — | $539.5M | ||
| Q2 24 | $9.5M | $637.2M | ||
| Q1 24 | — | $425.2M |
| Q1 26 | — | $244.5M | ||
| Q4 25 | — | $193.6M | ||
| Q3 25 | — | $184.8M | ||
| Q2 25 | — | $159.6M | ||
| Q1 25 | — | $139.9M | ||
| Q3 24 | — | $118.0M | ||
| Q2 24 | $-25.3M | $226.1M | ||
| Q1 24 | — | $37.3M |
| Q1 26 | — | 95.6% | ||
| Q4 25 | — | 96.9% | ||
| Q3 25 | — | 96.6% | ||
| Q2 25 | — | 96.5% | ||
| Q1 25 | — | 96.5% | ||
| Q3 24 | — | 96.8% | ||
| Q2 24 | — | 97.2% | ||
| Q1 24 | — | 95.0% |
| Q1 26 | — | 39.3% | ||
| Q4 25 | — | 39.6% | ||
| Q3 25 | — | 37.6% | ||
| Q2 25 | — | 33.6% | ||
| Q1 25 | — | 28.8% | ||
| Q3 24 | — | 25.2% | ||
| Q2 24 | -181.1% | 43.3% | ||
| Q1 24 | — | 6.9% |
| Q1 26 | — | 40.8% | ||
| Q4 25 | — | 32.4% | ||
| Q3 25 | — | 32.5% | ||
| Q2 25 | — | 28.7% | ||
| Q1 25 | — | 24.7% | ||
| Q3 24 | — | 21.9% | ||
| Q2 24 | -265.9% | 35.5% | ||
| Q1 24 | — | 8.8% |
| Q1 26 | — | $0.89 | ||
| Q4 25 | — | $0.69 | ||
| Q3 25 | — | $0.65 | ||
| Q2 25 | — | $0.55 | ||
| Q1 25 | — | $0.47 | ||
| Q3 24 | — | $0.40 | ||
| Q2 24 | $-0.28 | $0.77 | ||
| Q1 24 | — | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $149.0M | $1.1B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $148.6M | $2.2B |
| Total Assets | $407.1M | $2.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.1B | ||
| Q4 25 | — | $988.5M | ||
| Q3 25 | — | $791.1M | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $1.1B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | $149.0M | $1.0B | ||
| Q1 24 | — | $963.3M |
| Q1 26 | — | $2.2B | ||
| Q4 25 | — | $2.2B | ||
| Q3 25 | — | $2.0B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.2B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | $148.6M | $2.1B | ||
| Q1 24 | — | $2.1B |
| Q1 26 | — | $2.8B | ||
| Q4 25 | — | $2.8B | ||
| Q3 25 | — | $2.7B | ||
| Q2 25 | — | $2.8B | ||
| Q1 25 | — | $2.9B | ||
| Q3 24 | — | $3.0B | ||
| Q2 24 | $407.1M | $2.8B | ||
| Q1 24 | — | $2.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.9M | $333.5M |
| Free Cash FlowOCF − Capex | $27.6M | $332.4M |
| FCF MarginFCF / Revenue | 290.5% | 55.5% |
| Capex IntensityCapex / Revenue | 13.2% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 1.36× |
| TTM Free Cash FlowTrailing 4 quarters | — | $875.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $333.5M | ||
| Q4 25 | — | $290.3M | ||
| Q3 25 | — | $49.0M | ||
| Q2 25 | — | $211.4M | ||
| Q1 25 | — | $240.3M | ||
| Q3 24 | — | $271.3M | ||
| Q2 24 | $28.9M | $119.5M | ||
| Q1 24 | — | $68.8M |
| Q1 26 | — | $332.4M | ||
| Q4 25 | — | $288.8M | ||
| Q3 25 | — | $46.2M | ||
| Q2 25 | — | $208.5M | ||
| Q1 25 | — | $236.3M | ||
| Q3 24 | — | $263.1M | ||
| Q2 24 | $27.6M | $113.0M | ||
| Q1 24 | — | $59.1M |
| Q1 26 | — | 55.5% | ||
| Q4 25 | — | 48.3% | ||
| Q3 25 | — | 8.1% | ||
| Q2 25 | — | 37.5% | ||
| Q1 25 | — | 41.7% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | 290.5% | 17.7% | ||
| Q1 24 | — | 13.9% |
| Q1 26 | — | 0.2% | ||
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.7% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | 13.2% | 1.0% | ||
| Q1 24 | — | 2.3% |
| Q1 26 | — | 1.36× | ||
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 1.32× | ||
| Q1 25 | — | 1.72× | ||
| Q3 24 | — | 2.30× | ||
| Q2 24 | — | 0.53× | ||
| Q1 24 | — | 1.84× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
